Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals

Edward J Mills, Ping Wu, Ian Lockhart, Kumanan Wilson, Jon O Ebbert, Edward J Mills, Ping Wu, Ian Lockhart, Kumanan Wilson, Jon O Ebbert

Abstract

Background: Nicotine replacement therapy (NRT) is the most common form of smoking cessation pharmacotherapy and has proven efficacy for the treatment of tobacco dependence. Although expectations of mild adverse effects have been observed to be independent predictors of reduced motivation to use NRT, adverse effects associated with NRT have not been precisely quantified.

Objective: A systematic review and meta-analysis aimed to identify all randomized clinical trials (RCTs) of NRT versus inert controls and all observational studies to determine the magnitude of reported adverse effects with NRT.

Methods: Searches of 10 electronic databases from inception to November 2009 were conducted. Study selection and data extraction were carried out independently in duplicate. RCTs were pooled using a random effects method with Odds Ratio [OR] as the effect measure, while proportions were pooled from observational studies. A meta-regression analysis was applied to examine whether the nicotine patch is associated with different adverse effects from those common to orally administered NRT.

Results: Ninety-two RCTs involving 32,185 participants and 28 observational studies involving 145, 205 participants were identified. Pooled RCT evidence of varying NRT formulations found an increased risk of heart palpitations and chest pains (OR 2.06, 95% Confidence Interval [CI] 1.51-2.82, P < 0.001); nausea and vomiting (OR 1.67, 95% CI 1.37-2.04, P < 0.001); gastrointestinal complaints (OR 1.54, 95% CI, 1.25-1.89, P < 0.001); and insomnia (OR 1.42, 95% CI, 1.21-1.66, P < 0.001). Pooled evidence specific to the NRT patch found an increase in skin irritations (OR 2.80, 95% CO, 2.28-3.24, P < 0.001). Orally administered NRT was associated with mouth and throat soreness (OR 1.87, 95% CI, 1.36-2.57, P < 0.001); mouth ulcers (OR 1.49, 95% CI, 1.05-2.20, P < 0.001); hiccoughs (OR 7.68, 95% CI, 4.59-12.85, P < 0.001) and coughing (OR 2.89, 95% CI, 1.92-4.33, P < 0.001). There was no statistically significant increase in anxiety or depressive symptoms associated with NRT use. Non-comparative observational studies demonstrated the prevalence of these events in a broad population.

Conclusion: The use of NRT is associated with a variety of side effects. In addition to counseling and medical monitoring, clinicians should inform patients of potential side effects which are associated with the use of NRT for the treatment of tobacco dependence.

Figures

Figure 1
Figure 1
low-diagram of included studies.
Figure 2
Figure 2
Summary pooled estimates of adverse events reported in RCTs
Figure 3
Figure 3
Summary pooled estimates of adverse events reported in observational studies.

References

    1. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R. Mortality from smoking worldwide. Br Med Bull. 1996;52:12–21.
    1. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. Bmj. 1994;309:901–11.
    1. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007;370:2044–53. doi: 10.1016/S0140-6736(07)61698-5.
    1. Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health. 2006;6:300. doi: 10.1186/1471-2458-6-300.
    1. NICE. Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. Public Health Guidance PH10. 2008.
    1. Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Cmaj. 2008;179:135–44.
    1. Vjogt F, Hall S, Marteau TM. Understanding why smokers do not want to use nicotine dependence medications to stop smoking: qualitative and quantitative studies. Nicotine Tob Res. 2008;10:1405–13. doi: 10.1080/14622200802239280.
    1. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res. 2007;9:315–27. doi: 10.1080/14622200701188919.
    1. Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med. 2005;142:1090–9.
    1. Kuper H, Nicholson A, Hemingway H. Searching for observational studies: what does citation tracking add to PubMed? A case study in depression and coronary heart disease. BMC medical research methodology. 2006;6:4. doi: 10.1186/1471-2288-6-4.
    1. Tonnesen P. Smoking cessation: How compelling is the evidence? A review. Health policy (Amsterdam, Netherlands) 2009;91(Suppl 1):S15–25.
    1. Mills EJ, Wu P, Spurden D, Ebbert JO, Wilson K. Efficacy of pharmacotherapies for short-term smoking abstinance: A systematic review and meta-analysis. Harm Reduct J. 2009;6:25. doi: 10.1186/1477-7517-6-25.
    1. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane database of systematic reviews (Online) 2008. p. CD000146.
    1. Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane database of systematic reviews (Online) 2007. p. CD005231.
    1. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane database of systematic reviews (Online) 2007. p. CD006103.
    1. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health technology assessment (Winchester, England) 2002;6:1–245.
    1. Meade MO, Guyatt GH, Cook RJ, Groll R, Kachura JR, Wigg M. Agreement between alternative classifications of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163:490–3.
    1. Sheehe PR. Combination of log relative risk in retrospective studies of disease. Am J Public Health Nations Health. 1966;56:1745–50.
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. doi: 10.1016/0197-2456(86)90046-2.
    1. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121–45. doi: 10.1177/096228029300200202.
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. doi: 10.1002/sim.1186.
    1. Stuart A, Ord JK. Kendall's Advanced Theory of Statistics. 6. London: Edward Arnold; 1994.
    1. Borenstin M, Hedges L, Higgins JP, Rothstein H. Introduction to Meta-analysis. Wiley, Chichester; 2009. p. 312.
    1. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS medicine. 2006;3:e438. doi: 10.1371/journal.pmed.0030438.
    1. Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC medical research methodology. 2008;8:79. doi: 10.1186/1471-2288-8-79.
    1. Malcolm RE, Sillett RW, Turner JA, Ball KP. The use of nicotine chewing gum as an aid to stopping smoking. Psychopharmacology (Berl) 1980;70:295–6. doi: 10.1007/BF00427889.
    1. Jarvis MJ, Raw M, Russell MA, Feyerabend C. Randomised controlled trial of nicotine chewing-gum. Br Med J (Clin Res Ed) 1982;285:537–40. doi: 10.1136/bmj.285.6341.537.
    1. Fagerstrom KO. A comparison of psychological and pharmacological treatment in smoking cessation. J Behav Med. 1982;5:343–51. doi: 10.1007/BF00846161.
    1. Comparison of four methods of smoking withdrawal in patients with smoking related diseases. Report by a subcommittee of the Research Committee of the British Thoracic Society. Br Med J (Clin Res Ed) 1983;286:595–7. doi: 10.1136/bmj.286.6365.595.
    1. Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. Addict Behav. 1983;8:253–61. doi: 10.1016/0306-4603(83)90020-5.
    1. Jamrozik K, Fowler G, Vessey M, Wald N. Placebo controlled trial of nicotine chewing gum in general practice. Br Med J (Clin Res Ed) 1984;289:794–7. doi: 10.1136/bmj.289.6448.794.
    1. Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnersen AB, Forchammer H. Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. Addict Behav. 1988;13:17–27. doi: 10.1016/0306-4603(88)90021-4.
    1. Areechon W, Punnotok J. Smoking cessation through the use of nicotine chewing gum: a double-blind trial in Thailand. Clin Ther. 1988;10:183–6.
    1. Fortmann SP, Killen JD, Telch MJ, Newman B. Minimal contact treatment for smoking cessation. A placebo controlled trial of nicotine polacrilex and self-directed relapse prevention: initial results of the Stanford Stop Smoking Project. Jama. 1988;260:1575–80. doi: 10.1001/jama.260.11.1575.
    1. Harackiewicz JM, Blair LW, Sansone C, Epstein JA, Stuchell RN. Nicotine gum and self-help manuals in smoking cessation: an evaluation in a medical context. Addict Behav. 1988;13:319–30. doi: 10.1016/0306-4603(88)90038-X.
    1. Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnersen AB, Forchammer H. Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. N Engl J Med. 1988;318:15–8.
    1. Hughes JR, Gust SW, Keenan RM, Fenwick JW, Healey ML. Nicotine vs placebo gum in general medical practice. Jama. 1989;261:1300–5. doi: 10.1001/jama.261.9.1300.
    1. Blondal T. Controlled trial of nicotine polacrilex gum with supportive measures. Arch Intern Med. 1989;149:1818–21. doi: 10.1001/archinte.149.8.1818.
    1. Abelin T, Ehrsam R, Buhler-Reichert A, Imhof PR, Muller P, Thommen A. Effectiveness of a transdermal nicotine system in smoking cessation studies. Methods Find Exp Clin Pharmacol. 1989;11:205–14.
    1. Hurt RD, Lauger GG, Offord KP, Kottke TE, Dale LC. Nicotine-replacement therapy with use of a transdermal nicotine patch--a randomized double-blind placebo-controlled trial. Mayo Clin Proc. 1990;65:1529–37.
    1. Tonnesen P, Norregaard J, Simonsen K, Sawe U. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med. 1991;325:311–5.
    1. Campbell IA, Prescott RJ, Tjeder-Burton SM. Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum. Respir Med. 1991;85:155–7. doi: 10.1016/S0954-6111(06)80295-7.
    1. Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study. Arch Intern Med. 1991;151:749–52. doi: 10.1001/archinte.151.4.749.
    1. Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet. 1992;340:324–9. doi: 10.1016/0140-6736(92)91403-U.
    1. Sachs DP, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med. 1993;153:1881–90. doi: 10.1001/archinte.153.16.1881.
    1. Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. Jama. 1993;269:1268–71. doi: 10.1001/jama.269.10.1268.
    1. Merz PG, Keller-Stanislawski B, Huber T, Woodcock BG, Rietbrock N. Transdermal nicotine in smoking cessation and involvement of non-specific influences. Int J Clin Pharmacol Ther Toxicol. 1993;31:476–82.
    1. Russell MA, Stapleton JA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. Bmj. 1993;306:1308–12. doi: 10.1136/bmj.306.6888.1308.
    1. Westman EC, Levin ED, Rose JE. The nicotine patch in smoking cessation. A randomized trial with telephone counseling. Arch Intern Med. 1993;153:1917–23. doi: 10.1001/archinte.153.16.1917.
    1. Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch Intern Med. 1994;154:2567–72. doi: 10.1001/archinte.154.22.2567.
    1. Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. Jama. 1994;271:595–600. doi: 10.1001/jama.271.8.595.
    1. Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. Chest. 1994;105:524–33. doi: 10.1378/chest.105.2.524.
    1. Richmond RL, Harris K, de Almeida Neto A. The transdermal nicotine patch: results of a randomised placebo-controlled trial. Med J Aust. 1994;161:130–5.
    1. Levin ED, Westman EC, Stein RM, Carnahan E, Sanchez M, Herman S. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. J Clin Psychopharmacol. 1994;14:41–9. doi: 10.1097/00004714-199402000-00006.
    1. Stapleton JA, Russell MA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction. 1995;90:31–42. doi: 10.1111/j.1360-0443.1995.tb01007.x.
    1. Herrera N, Franco R, Herrera L, Partidas A, Rolando R, Fagerstrom KO. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest. 1995;108:447–51. doi: 10.1378/chest.108.2.447.
    1. Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction. 1995;90:1671–82. doi: 10.1111/j.1360-0443.1995.tb02837.x.
    1. Puska PKH, Vartiainen E, Urjanheimo E. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tabacco Control. 1995;4:231–5. doi: 10.1136/tc.4.3.231.
    1. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. 1995;24:41–7. doi: 10.1006/pmed.1995.1006.
    1. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. Jama. 1995;274:1353–8. doi: 10.1001/jama.274.17.1353.
    1. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. Bmj. 1995;311:363–6.
    1. Leischow SJN, Franzo F, Hill M, Otte A, Merikle P, E P. Efficacy of the Nicotine Inhaler as an Adjunct to Smoking Cessation. American Journal of Health Behavior. 1996;20:364–71.
    1. Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction. 1996;91:1293–306.
    1. Paoletti P, Fornai E, Maggiorelli F, Puntoni R, Viegi G, Carrozzi L. Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch. Eur Respir J. 1996;9:643–51. doi: 10.1183/09031936.96.09040643.
    1. Blondal T, Franzon M, Westin A. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Respir J. 1997;10:1585–90. doi: 10.1183/09031936.97.10071585.
    1. Campbell IA, Prescott RJ, Tjeder-Burton SM. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study. Respir Med. 1996;90:47–51. doi: 10.1016/S0954-6111(96)90244-9.
    1. Hjalmarson A, Nilsson F, Sjostrom L, Wiklund O. The nicotine inhaler in smoking cessation. Arch Intern Med. 1997;157:1721–8. doi: 10.1001/archinte.157.15.1721.
    1. Sonderskov J, Olsen J, Sabroe S, Meillier L, Overvad K. Nicotine patches in smoking cessation: a randomized trial among over-the-counter customers in Denmark. Am J Epidemiol. 1997;145:309–18.
    1. Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ. Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. J Formos Med Assoc. 1998;97:547–51.
    1. Ahluwalia JS, McNagny SE, Clark WS. Smoking cessation among inner-city African Americans using the nicotine transdermal patch. J Gen Intern Med. 1998;13:1–8. doi: 10.1046/j.1525-1497.1998.00001.x.
    1. Lewis SF, Piasecki TM, Fiore MC, Anderson JE, Baker TB. Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial. Prev Med. 1998;27:296–303. doi: 10.1006/pmed.1998.0266.
    1. Davidson M, Epstein M, Burt R, Schaefer C, Whitworth G, McDonald A. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. Arch Fam Med. 1998;7:569–74. doi: 10.1001/archfami.7.6.569.
    1. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. Bmj. 1999;318:285–8.
    1. Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. 1999;13:238–46. doi: 10.1034/j.1399-3003.1999.13b04.x.
    1. Hays JT, Croghan IT, Schroeder DR, Offord KP, Hurt RD, Wolter TD. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. Am J Public Health. 1999;89:1701–7. doi: 10.2105/AJPH.89.11.1701.
    1. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–91. doi: 10.1056/NEJM199903043400903.
    1. Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med. 2000;160:3128–34. doi: 10.1001/archinte.160.20.3128.
    1. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. Bmj. 2000;321:329–33. doi: 10.1136/bmj.321.7257.329.
    1. Garvey AJ, Kinnunen T, Nordstrom BL, Utman CH, Doherty K, Rosner B. Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob Res. 2000;2:53–63. doi: 10.1080/14622200050011303.
    1. Wallstrom M, Nilsson F, Hirsch JM. A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. Addiction. 2000;95:1161–71.
    1. Wisborg K, Henriksen TB, Jespersen LB, Secher NJ. Nicotine patches for pregnant smokers: A randomized controlled study. Obstet Gynecol. 2000;96:967–71. doi: 10.1016/S0029-7844(00)01071-1.
    1. Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. J Clin Psychopharmacol. 2002;22:487–95. doi: 10.1097/00004714-200210000-00008.
    1. Shiffman S, Gorsline J, Gorodetzky CW. Efficacy of over-the-counter nicotine patch. Nicotine Tob Res. 2002;4:477–83. doi: 10.1080/1462220021000018416.
    1. Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CC, Howell RM. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. Nicotine Tob Res. 2002;4:441–50. doi: 10.1080/1462220021000018443.
    1. Shiffman S, Dresler CM, Hajek P, Gilburt SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med. 2002;162:1267–76. doi: 10.1001/archinte.162.11.1267.
    1. Hand S, Edwards S, Campbell IA, Cannings R. Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support. Thorax. 2002;57:715–8. doi: 10.1136/thorax.57.8.715.
    1. Glavas D, Rumboldt M, Rumboldt Z. Smoking cessation with nicotine replacement therapy among health care workers: randomized double-blind study. Croat Med J. 2003;44:219–24.
    1. Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction. 2003;98:1395–402. doi: 10.1046/j.1360-0443.2003.00489.x.
    1. Hughes JR, Novy P, Hatsukami DK, Jensen J, Callas PW. Efficacy of nicotine patch in smokers with a history of alcoholism. Alcohol Clin Exp Res. 2003;27:946–54.
    1. Hanson K, Allen S, Jensen S, Hatsukami D. Treatment of adolescent smokers with the nicotine patch. Nicotine Tob Res. 2003;5:515–26. doi: 10.1080/14622200307243.
    1. Molyneux A, Lewis S, Leivers U, Anderton A, Antoniak M, Brackenridge A. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients. Thorax. 2003;58:484–8. doi: 10.1136/thorax.58.6.484.
    1. Smith SS, Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA. Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine Tob Res. 2003;5:99–109. doi: 10.1080/1462220021000060437.
    1. Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. Addiction. 2004;99:634–40. doi: 10.1111/j.1360-0443.2004.00711.x.
    1. Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics. 2005;115:e407–14. doi: 10.1542/peds.2004-1894.
    1. Batra A, Klingler K, Landfeldt B, Friederich HM, Westin A, Danielsson T. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clin Pharmacol Ther. 2005;78:689–96. doi: 10.1016/j.clpt.2005.08.019.
    1. Rennard SI, Glover ED, Leischow S, Daughton DM, Glover PN, Muramoto M. Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. Nicotine Tob Res. 2006;8:555–64. doi: 10.1080/14622200600789916.
    1. Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest. 2006;130:334–42. doi: 10.1378/chest.130.2.334.
    1. Hotham ED, Gilbert AL, Atkinson ER. A randomised-controlled pilot study using nicotine patches with pregnant women. Addict Behav. 2006;31:641–8. doi: 10.1016/j.addbeh.2005.05.042.
    1. Myung SK, Seo HG, Park S, Kim Y, Kim DJ, Lee do H. Sociodemographic and smoking behavioral predictors associated with smoking cessation according to follow-up periods: a randomized, double-blind, placebo-controlled trial of transdermal nicotine patches. J Korean Med Sci. 2007;22:1065–70. doi: 10.3346/jkms.2007.22.6.1065.
    1. Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction. 2007;102:1292–302. doi: 10.1111/j.1360-0443.2007.01887.x.
    1. Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC. Efficacy of bupropion alone and in combination with nicotine gum. Nicotine Tob Res. 2007;9:947–54. doi: 10.1080/14622200701540820.
    1. Oncken C, Cooney J, Feinn R, Lando H, Kranzler HR. Transdermal nicotine for smoking cessation in postmenopausal women. Addict Behav. 2007;32:296–309. doi: 10.1016/j.addbeh.2006.04.004.
    1. Uyar M, Filiz A, Bayram N, Elbek O, Herken H, Topcu A. A randomized trial of smoking cessation. Medication versus motivation. Saudi Med J. 2007;28:922–6.
    1. Pollak KI, Oncken CA, Lipkus IM, Lyna P, Swamy GK, Pletsch PK. Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am J Prev Med. 2007;33:297–305. doi: 10.1016/j.amepre.2007.05.006.
    1. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792–8. doi: 10.1056/NEJM199612123352402.
    1. Buchkremer G, Bents H, Minneker E, Opitz K. Long-term effects of a combination of transdermal nicotine administration with behavior therapy for smoking cessation. Nervenarzt. 1988;59:488–90.
    1. Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. Transdermal Nicotine Study Group. Jama. 1991;266:3133–8. doi: 10.1001/jama.266.22.3133.
    1. Jensen EJ, Schmidt E, Pedersen B, Dahl R. Effect of nicotine, silver acetate, and ordinary chewing gum in combination with group counselling on smoking cessation. Thorax. 1990;45:831–4. doi: 10.1136/thx.45.11.831.
    1. Hughes JR, Gust SW, Keenan RM, Fenwick JW. Effect of dose on nicotine's reinforcing, withdrawal-suppression and self-reported effects. J Pharmacol Exp Ther. 1990;252:1175–83.
    1. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63:717–24. doi: 10.1136/thx.2007.090647.
    1. Rubinstein ML, Benowitz NL, Auerback GM, Moscicki AB. A randomized trial of nicotine nasal spray in adolescent smokers. Pediatrics. 2008;122:e595–600. doi: 10.1542/peds.2008-0501.
    1. Warner DO, Patten CA, Ames SC, Offord KP, Schroeder DR. Effect of nicotine replacement therapy on stress and smoking behavior in surgical patients. Anesthesiology. 2005;102:1138–46. doi: 10.1097/00000542-200506000-00013.
    1. Murray RP, Bailey WC, Daniels K, Bjornson WM, Kurnow K, Connett JE. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. 1996;109:438–45. doi: 10.1378/chest.109.2.438.
    1. Sun HQ, Guo S, Chen DF, Jiang ZN, Liu Y, Di XL. Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in chinese smokers. Am J Drug Alcohol Abuse. 2009;35:183–8. doi: 10.1080/00952990902839794.
    1. Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction. 2009;104:266–76. doi: 10.1111/j.1360-0443.2008.02454.x.
    1. Shiffman S, Ferguson SG, Strahs KR. Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial. Am J Prev Med. 2009;36:96–104. doi: 10.1016/j.amepre.2008.09.039. e1.
    1. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66:1253–62. doi: 10.1001/archgenpsychiatry.2009.142.
    1. Hilleman DE, Mohiuddin SM, Delcore MG. Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation. J Clin Pharmacol. 1994;34:222–4.
    1. Orleans CT, Resch N, Noll E, Keintz MK, Rimer BK, Brown TV. Use of transdermal nicotine in a state-level prescription plan for the elderly. A first look at 'real-world' patch users. Jama. 1994;271:601–7. doi: 10.1001/jama.271.8.601.
    1. Smith TM, Winters FD. Smoking cessation: a clinical study of the transdermal nicotine patch. J Am Osteopath Assoc. 1995;95:655–6. 61-2.
    1. Martin PD, Robinson GM. The safety, tolerability and efficacy of transdermal nicotine (Nicotinell TTS) in initially hospitalised patients. N Z Med J. 1995;108:6–8.
    1. Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology (Berl) 1995;122:215–22. doi: 10.1007/BF02246542.
    1. Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT. Varying nicotine patch dose and type of smoking cessation counseling. Jama. 1995;274:1347–52. doi: 10.1001/jama.274.17.1347.
    1. Smith TA, House RF Jr, Croghan IT, Gauvin TR, Colligan RC, Offord KP. Nicotine patch therapy in adolescent smokers. Pediatrics. 1996;98:659–67.
    1. Hurt RD, Dale LC, Croghan GA, Croghan IT, Gomez-Dahl LC, Offord KP. Nicotine nasal spray for smoking cessation: pattern of use, side effects, relief of withdrawal symptoms, and cotinine levels. Mayo Clin Proc. 1998;73:118–25. doi: 10.4065/73.2.118.
    1. Gourlay SG, Forbes A, Marriner T, McNeil JJ. Predictors and timing of adverse experiences during trandsdermal nicotine therapy. Drug Saf. 1999;20:545–55. doi: 10.2165/00002018-199920060-00007.
    1. Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from higher dose nicotine patch therapy? Exp Clin Psychopharmacol. 1999;7:226–33. doi: 10.1037/1064-1297.7.3.226.
    1. Hurt RD, Croghan GA, Beede SD, Wolter TD, Croghan IT, Patten CA. Nicotine patch therapy in 101 adolescent smokers: efficacy, withdrawal symptom relief, and carbon monoxide and plasma cotinine levels. Arch Pediatr Adolesc Med. 2000;154:31–7.
    1. Shiffman S, Rolf CN, Hellebusch SJ, Gorsline J, Gorodetzky CW, Chiang YK. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction. 2002;97:505–16. doi: 10.1046/j.1360-0443.2002.00141.x.
    1. Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res. 2003;5:181–7. doi: 10.1080/1462220031000073252.
    1. Hasford J, Fagerstrom KO, Haustein KO. A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. Cohort study on smoking cessation. Eur J Clin Pharmacol. 2003;59:443–7. doi: 10.1007/s00228-003-0629-8.
    1. Fiore MC, McCarthy DE, Jackson TC, Zehner ME, Jorenby DE, Mielke M. Integrating smoking cessation treatment into primary care: an effectiveness study. Prev Med. 2004;38:412–20. doi: 10.1016/j.ypmed.2003.11.002.
    1. Carpenter MJ, Hughes JR, Solomon LJ, Callas PW. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. J Consult Clin Psychol. 2004;72:371–81. doi: 10.1037/0022-006X.72.3.371.
    1. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med. 2004;140:426–33.
    1. Hughes JR, Adams EH, Franzon MA, Maguire MK, Guary J. A prospective study of off-label use of, abuse of, and dependence on nicotine inhaler. Tob Control. 2005;14:49–54. doi: 10.1136/tc.2004.008367.
    1. Marsh HS, Dresler CM, Choi JH, Targett DA, Gamble ML, Strahs KR. Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study. Clin Ther. 2005;27:1571–87. doi: 10.1016/j.clinthera.2005.10.008.
    1. Bolliger CT, van Biljon X, Axelsson A. A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy. Respiration. 2007;74:196–201. doi: 10.1159/000097136.
    1. Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcliffe M. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103:146–54. doi: 10.1111/j.1360-0443.2007.02083.x.
    1. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. Bmj. 2009;339:b3805. doi: 10.1136/bmj.b3805.
    1. Ossip DJ, Abrams SM, Mahoney MC, Sall D, Cummings KM. Adverse effects with use of nicotine replacement therapy among quitline clients. Nicotine Tob Res. 2009;11:408–17. doi: 10.1093/ntr/ntp005.
    1. Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med. 2009;150:447–54.
    1. Oncken C, Dornelas E, Greene J, Sankey H, Glasmann A, Feinn R. Nicotine gum for pregnant smokers: a randomized controlled trial. Obstet Gynecol. 2008;112:859–67.
    1. Matthew TP, Herity NA. Acute myocardial infarction soon after nicotine replacement therapy. QJM. 2001;94:503–4. doi: 10.1093/qjmed/94.9.503.
    1. Dacosta A, Guy JM, Tardy B, Gonthier R, Denis L, Lamaud M. Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J. 1993;14:1709–11.
    1. Ottervanger JP, Festen JM, de Vries AG, Stricker BH. Acute myocardial infarction while using the nicotine patch. Chest. 1995;107:1765–6. doi: 10.1378/chest.107.6.1765.
    1. Ottervanger JP, Stricker BH, Klomps HC. Transdermal nicotine: clarifications, side effects, and funding. Jama. 1993;269:1940. doi: 10.1001/jama.269.15.1940. author reply -1.
    1. Rigotti NA, Eagle KA. Atrial fibrillation while chewing nicotine gum. Jama. 1986;255:1018. doi: 10.1001/jama.255.8.1018.
    1. Warner JG Jr, Little WC. Myocardial infarction in a patient who smoked while wearing a nicotine patch. Ann Intern Med. 1994;120:695.
    1. McRobbie H, Hajek P. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction. 2001;96:1547–51. doi: 10.1046/j.1360-0443.2001.961115472.x.
    1. McRobbie H, Hajek P, Gillison F. The relationship between smoking cessation and mouth ulcers. Nicotine Tob Res. 2004;6:655–9. doi: 10.1080/14622200410001734012.
    1. Hughes JR. Smoking and suicide: a brief overview. Drug Alcohol Depend. 2008;98:169–78. doi: 10.1016/j.drugalcdep.2008.06.003.
    1. Schroeder SA. A 51-year-old woman with bipolar disorder who wants to quit smoking. Jama. 2009;301:522–31. doi: 10.1001/jama.2008.982.
    1. Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. Sleep Med Rev. 2009.
    1. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. Bmj. 2005;330:396. doi: 10.1136/bmj.330.7488.396.
    1. Borenstein M, Hedges L, Higgins JP, Rothstein H. Introduction to Meta-analysis. Wiley, Chichester; 2009. p. 312.
    1. Thomsen T, Tonnesen H, Moller AM. Effect of preoperative smoking cessation interventions on postoperative complications and smoking cessation. Br J Surg. 2009;96:451–61. doi: 10.1002/bjs.6591.
    1. Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA) Eur Heart J. 2009;30:2769–812. doi: 10.1093/eurheartj/ehp337.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever